NCT00319228View on ClinicalTrials.gov

Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2028

Study Completion Date

March 31, 2029

Conditions
Antithrombin III Deficiency
Interventions
DRUG

Plasma-derived AT-III concentrate

"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."

All Listed Sponsors
lead

Grifols Biologicals, LLC

INDUSTRY